Gapping up
In reaction to strong earnings/guidance:
- UAL +4.3%, (provides Q3 investor update; raised its Q3 pre-tax margin guidance and updated other metrics)
- WMT +2.3%, (reaffirms FY18 guidance; sees FY19 EPS +5% with sales up at or above 3%; adds to share buyback)
- REVG +1.1%
M&A news:
- USEG +25.8% (sale of certain non-operated Williston Basin assets; received $2.0 million in cash)
- PFE +1% (reviewing strategic alternatives for its Consumer Healthcare business)
- HON +0.7% (announces planned comprehensive portfolio review)
Other news:
- KALV +75.4% (enters collaboration agreement with Merck (MRK); Merck to pay $37 mln upfront payment, additionally take 9.9% stake through private placement at $8.50/share)
- ANAB +57.1% (announces positive proof-of-concept data for ANB020)
- PSDV +12.3% (enters strategic collaboration agreement with Nicox to develop sustained release drug to lower intraocular pressure in patients with glaucoma)
- REPH +10.6% (presents clinical efficacy data from its Phase III study evaluating intravenous (IV) meloxicam 30mg)
- OVID +8.2% (receives orphan drug designation from the U.S. FDA for OV101)
- ICHR +5.9% (entered into 'substantial' agreement to produce liquid delivery systems for one of its key customers)
- NVDA +4.2% (announces new Drive PX Pegasus AI hardware that enables fully autonomous (level 5) driving - TechCrunch)
- ATRS +4% (enters into a definitive asset purchase agreement to sell the worldwide rights, including certain fixed assets, for the ZOMAJET )
- ALDX +2.6% (announces new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis), CLVS +1.8% ( submitted sNDA to the FDA for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy)
- DXC +1.2% (to acquire Logicalis SMC)
- REVG +1.1% (announces an underwritten public offering of 10,000,000 shares of common stock by certain selling stockholders)
- AGN +1% (FDA has accepted the NDA for ulipristal acetate)
Analyst comments:
- ABEO +4% (initiated with a Buy at Citigroup)
- PANW +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- RBS +2.5% (upgraded to Neutral from Underperform at Credit Suisse; upgraded to Neutral from Sell at Citigroup)
- RIG +1.6% (initiated with Buy ratings at Deutsche Bank)
- TSM +1.5% (upgraded to Overweight from Neutral at JP Morgan)
- DVN +1.4% (upgraded to Buy at Jefferies)
- DO +1.3% (upgraded to Neutral from Sell at FBR & Co)
- TSLA +1.2% (target raised to $379 from $317 at Morgan Stanley)
- LYG +0.8% (upgraded to Outperform from Neutral at Credit Suisse)
- CXO +0.8% (upgraded to Buy at Jefferies)
- CAT +0.7% (target raised to $158 at Goldman - new street high)
- CLB +0.7% (initiated with Buy ratings at Deutsche Bank)
- HAL +0.5% (initiated with Buy ratings at Deutsche Bank)